共 83 条
[1]
Brunzell J.D.(2002)Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 3143-21
[2]
Davidson M.(2008)Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation Diabetes Care 31 811-22
[3]
Furberg C.D.(2009)Standards of medical care in diabetes — 2009 Diabetes Care 32 S13-61
[4]
Sarwar N.(2007)Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies Circulation 115 450-8
[5]
Danesh J.(2007)Risk of cardiovascular events in patients at optimal values for combined lipid parameters Curr Med Res Opin 23 553-63
[6]
Eiriksdottir G.(2009)Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study Diabetes Care 32 493-8
[7]
Stanek E.J.(2006)Extent to which accepted serum lipid goals are achieved in a contemporary general medical population with coronary heart disease risk equivalents Am J Cardiol 98 1231-3
[8]
Sarawate C.(2006)Results of retrospective chart review to determine improvement in lipid goal attainment in patients treated by high-volume prescribers of lipid-modifying drugs J Manag Care Pharm 12 745-51
[9]
Willey V.J.(2008)Lipid therapy utilization rates in a managed-care mixed dyslipidemia population J Clin Lipidol 2 365-74
[10]
Scott R.(2009)Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia Am J Cardiol 103 515-22